Pay in 4 interest-free payments of $6.34 Learn more
Ships within 48 hours · Estimated delivery Nov 14 - Nov 19
1 ,2 About the REDEFINE 1 trial REDEFINE 1 was a double-blind, placebo-and active-controlled 68-week efficacy and safety phase 3 trial of once-weekly CagriSema (cagrilintide 2.4 mg and semaglutide 2.4 mg), cagrilintide 2.4 mg monotherapy and semaglutide 2.4 mg monotherapy versus placebo in 3,417 adults with obesity (BMI 30 kg/m 2 ), or overweight (BMI 27 kg/m 2 ) with one or more obesity-related comorbidities, and without type 2 diabetes
If readers choose to click on these links and make a purchase, the publisher or associated third parties may receive a commission at no additional cost to the consumer
Erratum.In:EurJPrevCardiol.2022Dec14 Lengton R, Iyer AM, van der Valk ES, Hoogeveen EK, Meijer OC, van der Voorn B, van Rossum EFC (2022) Variation in glucocorticoid sensitivity and the relation with obesity
259 SarkarA.Shamsuzzama, KumarL.HameedR.NazirA
US$ 20.30
US$ 25.34
US$ 28.31
US$ 24.54
US$ 20.61
US$ 24.27
US$ 20.96
